PP

Praveen Praveen

Active Director Director DIN 05129310
DIN 05129310 First appointment Feb 2012 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Feb 2012
Shareholding value •••• Premium profile

About Praveen Praveen

Data last updated:

Praveen Praveen is a Director at Sphygmose Pharmaceutical Private Limited (since 2012). The company operates in Pharma. Sphygmose Pharmaceutical Private Limited reported revenue of ₹18.3 Lakh (FY 2025).

DIN 05129310
Primary Designation Director
Industry Pharma
First Appointment 02 Feb 2012
Oldest Company Age 14 yrs
Largest company Sphygmose Pharmaceutical Private Limited · ₹18.3 Lakh (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director02 Feb 20122012₹18.3 Lakh (FY 2025)Active

Board colleagues of Praveen Praveen

Directorship timeline

Open interactive timeline →
Sphygmose Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Praveen Praveen

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Praveen Praveen

Praveen Praveen currently holds 1 directorship: Sphygmose Pharmaceutical Private Limited (Director, since 02 Feb 2012, revenue ₹18.3 Lakh (FY 2025)).

Praveen Praveen was first appointed on 02 Feb 2012 as Director at Sphygmose Pharmaceutical Private Limited.

The current boards of Praveen Praveen's companies include Jayasankar Unnikrishnan Cheenikuzhi (Sphygmose Pharmaceutical Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available